Atai Life Sciences announces first patient dosed in Elumina Phase 2 trial
Life Sciences (ATAI) announced that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral ...
A Psychedelic Molecule Controls Your Consciousness at the Moment of Death, New Theory Suggests
Some researchers believe DMT, a powerful psychedelic that may naturally occur in the brain, could be your soul’s “ferryman.” ...
European Medical Journal2d
Phase 2 trial begins for psychedelic-based depression treatment
A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.
Researchers Uncover Intriguing Connection Between DMT, Heart Activity
DMT (N,N-Dimethyltryptamine ) is a psychedelic known for inducing intense states of consciousness. This psychedelic naturally occurs in different pla ...
Hosted on MSN7mon
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
VLS-01, an oral formulation of N,N-dimethyltryptamine (DMT), is designed to be administered via a buccal film applied to the lining of the cheek. This delivery method aims to induce a short ...
Nature3y
Psychedelic-assisted therapy: a new approach to treating depression
N-dimethyltryptamine (DMT). “Combining pharmacological and psychological intervention is a departure from existing practices so we’re treading on virgin territory,” said Small Pharma chief ...
Yahoo Finance22d
Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio
today announced a licensing agreement (the "Agreement") under which atai has acquired Psilera's DMT (N,N-dimethyltryptamine) patent portfolio, including all granted and pending patents related to ...